ACP3 and prostate cancer: Sipuleucel-T (APC8015), a cancer vaccine, is an active cellular immunotherapy that stimulates a prostate cancer-specific T-cell immune response against prostatic acid phosphatase (PAP), an antigen expressed by approximately 95% of prostate cancer cells [82–84].